<DOC>
	<DOCNO>NCT01560468</DOCNO>
	<brief_summary>This study test safety tolerability HCV Entry Inhibitor ITX 5061 Liver Transplant Recipients Hepatitis C infection . The investigator hypothesize ITX 5061 oral monotherapy safe adult liver transplantation therapy also inhibit HCV infection newly transplant liver adult prior HCV infection .</brief_summary>
	<brief_title>Study Hepatitis C Virus ( HCV ) Entry Inhibitor Liver Transplant Recipients With HCV Infection</brief_title>
	<detailed_description>All subject receive 28 day ITX 5061 begin time transplant . Dosing ITX 5061 follow : Day Transplant prior surgery : ITX 5061 300 mg Day Transplant follow surgery : ITX 5061 300 mg Post-Operative Days 1-6 : ITX 5061 300 mg Post-Operative Days 7-27 : ITX 5061 150 mg Subjects monitor HCV RNA level , HDL cholesterol ITX 5061 drug concentration level . A liver biopsy perform 6 month post-transplant assess histological sign HCV recurrence .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Age 1872 Patients accept onto wait list liver transplantation HCV relate liver disease receive decease donor liver allograft HCV RNA ( + ) time list transplantation . All HCV genotype eligible Patients HCC receive hepatitis B core ( + ) donor liver eligible Standard immunosuppression protocol tacrolimus , corticosteroid taper , mycophenolate mofetil Viral coinfection ( HBV/HIV ) Receipt HCV ( + ) donor allograft Patients undergoing retransplantation recurrent HCV Multivisceral transplantation Patients receive antiviral therapy time LT Live donor liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C Virus Infection</keyword>
	<keyword>Liver Transplantation</keyword>
</DOC>